These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39412913)

  • 41. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
    Adesso L; Calabretta S; Barbagallo F; Capurso G; Pilozzi E; Geremia R; Delle Fave G; Sette C
    Oncogene; 2013 Jun; 32(23):2848-57. PubMed ID: 22797067
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
    Al-Ejeh F; Pajic M; Shi W; Kalimutho M; Miranda M; Nagrial AM; Chou A; Biankin AV; Grimmond SM; ; Brown MP; Khanna KK
    Clin Cancer Res; 2014 Jun; 20(12):3187-97. PubMed ID: 24838526
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells.
    Ammerpohl O; Trauzold A; Schniewind B; Griep U; Pilarsky C; Grutzmann R; Saeger HD; Janssen O; Sipos B; Kloppel G; Kalthoff H
    Br J Cancer; 2007 Jan; 96(1):73-81. PubMed ID: 17164759
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development and
    Urey C; Hilmersson KS; Andersson B; Ansari D; Andersson R
    Anticancer Res; 2017 Nov; 37(11):6031-6039. PubMed ID: 29061782
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death.
    Passacantilli I; Panzeri V; Terracciano F; Delle Fave G; Sette C; Capurso G
    Oncol Rep; 2018 Apr; 39(4):1984-1990. PubMed ID: 29393478
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
    Avan A; Quint K; Nicolini F; Funel N; Frampton AE; Maftouh M; Pelliccioni S; Schuurhuis GJ; Peters GJ; Giovannetti E
    Curr Pharm Des; 2013; 19(5):940-50. PubMed ID: 22973962
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance.
    D'Errico G; Alonso-Nocelo M; Vallespinos M; Hermann PC; Alcalá S; García CP; Martin-Hijano L; Valle S; Earl J; Cassiano C; Lombardia L; Feliu J; Monti MC; Seufferlein T; García-Bermejo L; Martinelli P; Carrato A; Sainz B
    Oncogene; 2019 Jul; 38(27):5469-5485. PubMed ID: 30936462
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models.
    Dunlop CR; Wallez Y; Johnson TI; Bernaldo de Quirós Fernández S; Durant ST; Cadogan EB; Lau A; Richards FM; Jodrell DI
    Br J Cancer; 2020 Oct; 123(9):1424-1436. PubMed ID: 32741974
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.
    Olive KP; Jacobetz MA; Davidson CJ; Gopinathan A; McIntyre D; Honess D; Madhu B; Goldgraben MA; Caldwell ME; Allard D; Frese KK; Denicola G; Feig C; Combs C; Winter SP; Ireland-Zecchini H; Reichelt S; Howat WJ; Chang A; Dhara M; Wang L; Rückert F; Grützmann R; Pilarsky C; Izeradjene K; Hingorani SR; Huang P; Davies SE; Plunkett W; Egorin M; Hruban RH; Whitebread N; McGovern K; Adams J; Iacobuzio-Donahue C; Griffiths J; Tuveson DA
    Science; 2009 Jun; 324(5933):1457-61. PubMed ID: 19460966
    [TBL] [Abstract][Full Text] [Related]  

  • 54. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
    Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
    Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interferon-alpha restitutes the chemosensitivity in pancreatic cancer.
    Hoffmann K; Mehrle S; Schmidt J; Büchler MW; Märten A
    Anticancer Res; 2008; 28(3A):1499-507. PubMed ID: 18630504
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy.
    Michienzi S; Bucci B; Verga Falzacappa C; Patriarca V; Stigliano A; Panacchia L; Brunetti E; Toscano V; Misiti S
    J Endocrinol; 2007 May; 193(2):209-23. PubMed ID: 17470512
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer.
    Thakur PC; Miller-Ocuin JL; Nguyen K; Matsuda R; Singhi AD; Zeh HJ; Bahary N
    J Transl Med; 2018 Jul; 16(1):190. PubMed ID: 29986726
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.
    Awasthi N; Kirane A; Schwarz MA; Toombs JE; Brekken RA; Schwarz RE
    BMC Cancer; 2011 Jan; 11():15. PubMed ID: 21226944
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal Adenocarcinoma.
    Shah A; Jahan R; Kisling SG; Atri P; Natarajan G; Nallasamy P; Cox JL; Macha MA; Sheikh IA; Ponnusamy MP; Kumar S; Batra SK
    Cancer Lett; 2024 Aug; 598():217097. PubMed ID: 38964729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.